CHAIRMAN OF THE BOARD
In his career, Dr. Reinhard Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. Among others, he developed the Novartis Venture Fund, one of the largest corporate biotechnology venture funds in the life sciences industry. He serves on the board of public and private biotechnology companies in Europe and the US, and as an advisor to German and Swiss Government Biotechnology Funds.
Dr. Michael Baran is Executive Director, Pfizer Worldwide Research and Development and Partner at Pfizer Venture, where he is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He joined Pfizer in 2008 in the market access space, providing strategic and analytical support around marketing and managed care contracting with commercial and government payers.
Dr. Markus Hosang is a General Partner of BioMedPartners AG, Basel, Switzerland. Beforehand, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for the European deal flow, managed the European office in Munich, and served on the board of several portfolio companies.
Dr. Daniel Vasella served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis AG from 1996 to January 2010. From 1992 to 1996, Dr. Vasella held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President and Head of Worldwide Development and Head of Corporate Marketing at Sandoz Pharma Ltd. Dr. Vasella is currently working as a strategic advisor and coach to senior executives. He is also a director of PepsiCo and American Express Company, and a member of several non-profit organizations.
CEO & DIRECTOR
Sean R. Smith is CEO and a member of the Board of Directors of ImmunOs Therapeutics AG since May of 2017. Sean R. Smith previously spent over 15 years at MSD/Merck and Co., Inc in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, country and regional operations with broad exposure to multiple therapeutic areas including early-stage clinical, in-line, and launch portfolios in hospital / specialty, infectious disease, general medicine, and vaccines.